Comparing virtual and in-person COPD care transition programs
The Reducing Respiratory Emergency Visits Using Implementation Science Interventions Tailored to Setting (REVISITS) Study: A Cluster Randomized Trial
NA · University of Chicago · NCT05568043
This study is testing whether virtual or in-person care programs help people with COPD avoid hospital visits and improve their overall care.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 24 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Chicago (other) |
| Locations | 1 site (Chicago, Illinois) |
| Trial ID | NCT05568043 on ClinicalTrials.gov |
What this trial studies
This trial evaluates the effectiveness of virtual versus in-person care transition programs for patients with COPD, utilizing a mentored implementation approach. Up to 24 hospitals will be randomized into four groups to receive either virtual or in-person interventions, with some also incorporating co-design methods. The goal is to determine which approach is most effective in reducing acute care revisits and ensuring sustainable implementation of evidence-based interventions. The study will span one year, focusing on quality improvement efforts tailored to each hospital's needs.
Who should consider this trial
Good fit: Ideal candidates for this study are hospitals that treat diverse patient populations with COPD across the United States.
Not a fit: Patients who are not part of the hospital systems involved in the trial may not receive any direct benefit.
Why it matters
Potential benefit: If successful, this study could lead to improved management of COPD and reduced hospital readmissions for patients.
How similar studies have performed: Other studies have shown promise in using virtual care models for chronic disease management, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Since enrollment for Aim 2 will occur on a site/system-level, the inclusion of specific individuals who meet these criteria are not applicable since Aim 2 will only enroll hospital sites, not individuals. The sites the investigators enroll will represent diverse patient populations and geographical locations across the US.
Where this trial is running
Chicago, Illinois
- University of Chicago — Chicago, Illinois, United States (RECRUITING)
Study contacts
- Principal investigator: Valerie Press — University of Chicago
- Study coordinator: Leah Traeger
- Email: LTraeger@bsd.uchicago.edu
- Phone: 847-508-3011
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: COPD, COPD Exacerbation Acute